App-Quantinova.ai

Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Catherine Thieblemont - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status

Olivier Decaux - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Multiple Myeloma

Dexamethasone

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Katharina M Lang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Myeloid neoplasms

N/A

Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program

Eric Deconinck - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Blastic plasmacytoid dendritic cell neoplasm

Tagraxofusp

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Molly Tokaz - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Ruben Mesa - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Hydroxyurea

Profile of Perioperative Coagulation in Major Liver Resection for Cancer: A Prospective Observational Study

Patrick Van Dreden - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fibrinogen (IV)

Amplified Thrombo-Inflammatory Biomarkers in Pulmonary Embolism with Augmented Responses in Von-Willebrand Factor, Microparticles and Interleukin-6 in Patients with Cancer

Fakiha Siddiqui - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary embolism

ILS-969

Elevated Thrombin Generation Biomarkers and Their Relevance with Decreased Thrombin Generation Potential in Patients with Pulmonary Embolism

Fakiha Siddiqui - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary embolism

Evithrom

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Hanny Al-Samkari - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Carboplatin

Cancer Cells and Platelets Have a Synergistic Role on the Acceleration of Clot Formation and Fibrin Polymerization. a Thromboelastometric Study

Elisabeth Mbemba - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Doxorubicin

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

Richa Rai - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

N/A

5-Azacytidine and Venetoclax Combination Boost Vγ9Vδ2 T Cell Effector Functions

Anne-Charlotte Le Floch - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

5-Azacytidine

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Olivier Demaria - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

B-Cell Non-Hodgkin Lymphoma

Obinutuzumab

Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Cristina Papayannidis - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute promyelocytic leukemia

L-Tyrosine

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Uwe Platzbecker - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Blastic plasmacytoid dendritic cell neoplasm

Tagraxofusp

Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia

Bochra Sedaki - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

amphotericin B

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Arsène Vacherot - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

High Tumor Mutation Burden in Epigenetic Regulatory Genes Predicts Decreased Overall Survival in Nodal Peripheral T-Cell Lymphomas

Luis Alberto de Padua Covas Lage - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

5-Azacytidine

Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma

Alejandro Berkovits - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Brain metastasis

Pembrolizumab

Filters

24360 Abstracts